Rating for Alnylam Pharmaceuticals climbed into a new percentile Friday, as it got a lift from 69 to 76.Please watch the video at Investors.com - Do Your Stocks Meet This Key Standard? Here's Why ...

Researchers at Kyushu University have developed a device that combines a catalyst and microwave flow reaction to efficiently convert ...

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...

Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Catalyst Therapeutics' controversial, $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...

It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on the announcement of a study failure, while Hoth Therapeutics HOTH gained on ...

The novel method utilizes sporopollenin, a naturally abundant waste product, as a scaffold for the growth of copper oxide ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced ...